# Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

> **NCT00883558** · PHASE2 · COMPLETED · sponsor: **Halozyme Therapeutics** · enrollment: 48 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Insulin Lispro
- **DRUG:** regular human insulin
- **DRUG:** recombinant human hyaluronidase PH20
- **DRUG:** Insulin glargine

## Key facts

- **NCT ID:** NCT00883558
- **Lead sponsor:** Halozyme Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-02
- **Final completion:** 2010-04
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00883558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00883558, "Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00883558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*